Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARITY: Prophylactic Antibiotic Regimens in Tumor Surgery
2014-004961-26Phase 3Active
- Sponsor
- McMaster University
- Start
- Nov 2015
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefazolin in bone cancer, soft tissue sarcoma (STS) and surgical site infection (SSI) (2 arms), sponsored by McMaster University. Primary endpoint: Surgical site infection within 1 year. Started Nov 2015; status: active.
02
Drugs
cefazolin
03
Conditions
bone cancersoft tissue sarcoma (STS)surgical site infection (SSI)
Beyond the preview
Go deeper on 2014-004961-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004961-26.